Iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors: A single-arm, multicenter, pivotal, phase II study

被引：0
|
作者：
Guo, Weijian
Bi, Feng
Dong, Jian
Jin, Chuan
Niu, Zuoxing
Wang, Yusheng
Sun, Meili
Wang, Teng
Yu, Dajun
He, Yifu
Zhang, Ruixing
Yin, Xianli
Feng, Wenlei
Zhang, Meijiang
Zhang, Baihui
Li, Lingyan
Kang, Xiaoyan
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Dept Gastrointestinal Oncol, Shanghai, Peoples R China
[2] Sichuan Univ, Dept Abdominal Oncol, West China Hosp, West China Sch Med, Chengdu, Peoples R China
[3] Kunming Med Univ, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China
[4] Guangzhou Med Univ, Affiliated Tumor Hosp, Guangzhou, Peoples R China
[5] Shandong Canc Hosp, Jinan, Peoples R China
[6] Shanxi Canc Hosp, Taiyuan, Peoples R China
[7] Shandong First Med Univ, Dept Oncol, Cental Hosp, Dept Oncol, Jinan, Peoples R China
[8] Jiangnan Univ, Affiliated Hosp, Dept Oncol, Wuxi Peoples Hosp 4, Wuxi, Jiangsu, Peoples R China
[9] Bengbu Med Coll, Affiliated Hosp 1, Surg Oncol, Bengbu, Peoples R China
[10] Anhui Prov Canc Hosp, Hefei, Peoples R China
[11] Hebei Med Univ, Hebei Canc Hosp, Hosp 4, Dept Gastroenterol, Shijiazhuang, Hebei, Peoples R China
[12] Hunan Canc Hosp, Changsha, Peoples R China
[13] Qilu Pharmaceut Co Ltd, Dept Oncol, Jinan, Peoples R China
[14] Qilu Pharmaceut Co Ltd, Clin Res Ctr, Jinan, Peoples R China
[15] Qilu Pharmaceut Co Ltd, Clin Res Ctr, Jinan, Shandong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3578
引用
收藏
页数：1
相关论文
共 50 条
  • [31] SAFETY PROFILE OF NIVOLUMAB plus IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH DNA MISMATCH REPAIR-DEFICIENT/MICROSATELLITE INSTABILITY-HIGH (DMMR/MSI-H) METASTATIC COLORECTAL CANCER (MCRC) IN CHECKMATE-142
    Brutcher, Edith
    Khoukaz, Taline
    Hartman, Leighanne
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [32] A phase 3 study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW
    Andre, T.
    Van Cutsem, E.
    Elez, E.
    Bennouna, J.
    de la Fouchardiere, C.
    Yoshino, T.
    Jensen, L.
    Mendez, G.
    Li, J.
    Goekkurt, E.
    Abdullaev, S.
    Chen, T.
    Lei, M.
    Lonardi, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S250 - S250
  • [33] Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.
    Overman, Michael J.
    Lenz, Heinz-Josef
    Andre, Thierry
    Aglietta, Massimo
    Wong, Mark Ka
    Luppi, Gabriele
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hendlisz, Alain
    Cardin, Dana Backlund
    Morse, Michael
    Neyns, Bart
    Hill, Andrew Graham
    Limon, M. Luisa
    Garcia-Alfonso, Pilar
    Krishnamurthy, Anuradha
    Chen, Franklin
    Abdullaev, Sandzhar
    Soleymani, Samira
    Lonardi, Sara
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [34] Clinical efficacy and biomarker analysis of pucotenlimab (HX008) in patients with previously treated advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A single-arm, multicenter, phase 2 study.
    Zhang, Bo
    Song, Yan
    Luo, Suxia
    Yin, Xianli
    Li, Enxiao
    Wang, Hui
    He, Yifu
    Liu, Zhihui
    Fan, Qingxia
    Liang, Xinjun
    Shu, Yongqian
    Liu, Yunpeng
    Xu, Nong
    Zhang, Shu
    Zhuang, Zhixiang
    Zhang, Jingdong
    Kou, Xiaoge
    Wang, Fen
    Zhu, Xiaodong
    Huang, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 799 - 799
  • [35] The efficacy and safety of neoadjuvant immunotherapy in patients with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) localized and oligometastatic colon cancer: Data from the real world.
    Chakrabarti, Sakti
    Parish, Marie
    Peterson, Carrie
    Ludwig, Kirk A.
    Sriram, Deepika
    Ruggeri, Antony
    Tolay, Sameer
    Selfridge, Jennifer Eva
    Bajor, David L.
    Mohamed, Amr
    Mahipal, Amit
    Shreenivas, Aditya V.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 105 - 105
  • [36] Preoperative (neoadjuvant) therapy with tislelizumab for locally advanced colorectal cancer with high microsatellite instability or deficient mismatch repair: An open-label, single-arm, multicenter phase II study.
    Ding, Ke-Feng
    Chen, Gong
    Ye, Yao
    Liu, Yue
    Sun, Yanlai
    Gao, Yang
    Zhang, Jingdong
    Wei, Shaozhong
    Li, Cong
    Li, Dandan
    Zhou, Yanbing
    Liu, Mulin
    Zhang, Juan
    Zhang, Lilin
    Kong, Dalu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study.
    Oaknin, Ana
    Pothuri, Bhavana
    Gilbert, Lucy
    Sabatier, Renaud
    Ghamande, Sharad A.
    Gravina, Adriano
    Calvo, Emiliano
    Banerjee, Susana N.
    Miller, Rowan
    Pikiel, Joanna
    Mirza, Mansoor Raza
    Duan, Tao
    Zildjian, Sybil
    Zografos, Eleftherios
    Veneris, Jennifer Taylor
    Tinker, Anna
    Powell, Matthew A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study
    Andre, Thierry
    Tougeron, David
    Piessen, Guillaume
    De La Fouchardiere, Christelle
    Louvet, Christophe
    Adenis, Antoine
    Jary, Marine
    Tournigand, Christophe
    Aparicio, Thomas
    Desrame, Jerome
    Lievre, Astrid
    Garcia-Larnicol, Marie-Line
    Pudlarz, Thomas
    Henriques, Julie
    Cohen, Romain
    Lefevre, Jeremie
    Svrcek, Magali
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [39] A phase III study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy (CT) for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Checkmate 8HW
    Abdullaev, Sandzhar
    Andre, Thierry
    Lei, Ming
    Lenz, Heinz-Josef
    Novotny, James
    Paulson, Andrew Scott
    Tejpar, Sabine
    Yamazaki, Kentaro
    Ledeine, Jean-Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [40] A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer
    Kim, Jwa Hoon
    Kim, Sun Young
    Baek, Ji Yeon
    Cha, Yong Jun
    Ahn, Joong Bae
    Kim, Han Sang
    Lee, Keun-Wook
    Kim, Ji-Won
    Kim, Tae-You
    Chang, Won Jin
    Park, Joon Oh
    Kim, Jihun
    Kim, Jeong Eun
    Hong, Yong Sang
    Kim, Yeul Hong
    Kim, Tae Won
    CANCER RESEARCH AND TREATMENT, 2020, 52 (04): : 1135 - 1144
12345